YYLSG
2021-11-24
Like
Outlook Shares Plunges After Raising $50M Via Equity Offering Issued At 20% Discount
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
1
12
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":874669498,"tweetId":"874669498","gmtCreate":1637767023325,"gmtModify":1637767023418,"author":{"id":3585128891404621,"idStr":"3585128891404621","authorId":3585128891404621,"authorIdStr":"3585128891404621","name":"YYLSG","avatar":"https://static.tigerbbs.com/41bee2bd52d9d3dc3a494bc99d85290d","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":13,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Like</p></body></html>","htmlText":"<html><head></head><body><p>Like</p></body></html>","text":"Like","highlighted":1,"essential":1,"paper":1,"likeSize":12,"commentSize":1,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/874669498","repostId":1182883462,"repostType":4,"repost":{"id":"1182883462","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1637765117,"share":"https://www.laohu8.com/m/news/1182883462?lang=&edition=full","pubTime":"2021-11-24 22:45","market":"us","language":"en","title":"Outlook Shares Plunges After Raising $50M Via Equity Offering Issued At 20% Discount","url":"https://stock-news.laohu8.com/highlight/detail?id=1182883462","media":"Benzinga","summary":"Outlook shares plunged more than 22% in early trading.Outlook Therapeutics Inc has increased the siz","content":"<p>Outlook shares plunged more than 22% in early trading.<img src=\"https://static.tigerbbs.com/400d88d0cf7a467f2553f97a56faba44\" tg-width=\"868\" tg-height=\"610\" referrerpolicy=\"no-referrer\"><b>Outlook Therapeutics Inc</b> has increased the size of the previously announced public offering to 40 million shares at $1.25 per share, for gross proceeds of $50 million. The offer price represents a discount of almost 20% from the last close price of $1.56 on Tuesday.</p>\n<p>Previously, the Company offered 8 million shares at $1.25 per share.</p>\n<p>The offering will close by November 29.</p>\n<p>H.C. Wainwright & Co. is acting as the sole book-running manager for the offering.</p>\n<p>GMS Ventures and Investments, an affiliate of Outlook Therapeutics' largest stockholder and strategic partner, BioLexis Pte. Ltd., has indicated an interest in purchasing directly or through an affiliate up to $20 million of the shares in the offering.</p>\n<p>Outlook Therapeutics will use the net proceeds for working capital and general corporate purposes, including supporting its ONS-5010 development program.</p>\n<p>Recently, Outlook presented pivotal safety and efficacy data from the Phase 3 NORSE TWO trial for ONS-5010 at the Retinal Subspecialty Day, AAO 2021 Annual Conference.</p>\n<p>ONS-5010 is an investigational ophthalmic formulation of bevacizumab for use in wet age-related macular degeneration (wet AMD) and other retinal indications,</p>\n<p>Outlook Therapeutics plans to submit a marketing application in Q1 of 2022.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Outlook Shares Plunges After Raising $50M Via Equity Offering Issued At 20% Discount</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOutlook Shares Plunges After Raising $50M Via Equity Offering Issued At 20% Discount\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2021-11-24 22:45</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>Outlook shares plunged more than 22% in early trading.<img src=\"https://static.tigerbbs.com/400d88d0cf7a467f2553f97a56faba44\" tg-width=\"868\" tg-height=\"610\" referrerpolicy=\"no-referrer\"><b>Outlook Therapeutics Inc</b> has increased the size of the previously announced public offering to 40 million shares at $1.25 per share, for gross proceeds of $50 million. The offer price represents a discount of almost 20% from the last close price of $1.56 on Tuesday.</p>\n<p>Previously, the Company offered 8 million shares at $1.25 per share.</p>\n<p>The offering will close by November 29.</p>\n<p>H.C. Wainwright & Co. is acting as the sole book-running manager for the offering.</p>\n<p>GMS Ventures and Investments, an affiliate of Outlook Therapeutics' largest stockholder and strategic partner, BioLexis Pte. Ltd., has indicated an interest in purchasing directly or through an affiliate up to $20 million of the shares in the offering.</p>\n<p>Outlook Therapeutics will use the net proceeds for working capital and general corporate purposes, including supporting its ONS-5010 development program.</p>\n<p>Recently, Outlook presented pivotal safety and efficacy data from the Phase 3 NORSE TWO trial for ONS-5010 at the Retinal Subspecialty Day, AAO 2021 Annual Conference.</p>\n<p>ONS-5010 is an investigational ophthalmic formulation of bevacizumab for use in wet age-related macular degeneration (wet AMD) and other retinal indications,</p>\n<p>Outlook Therapeutics plans to submit a marketing application in Q1 of 2022.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"OTLK":"Outlook Therapeutics, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1182883462","content_text":"Outlook shares plunged more than 22% in early trading.Outlook Therapeutics Inc has increased the size of the previously announced public offering to 40 million shares at $1.25 per share, for gross proceeds of $50 million. The offer price represents a discount of almost 20% from the last close price of $1.56 on Tuesday.\nPreviously, the Company offered 8 million shares at $1.25 per share.\nThe offering will close by November 29.\nH.C. Wainwright & Co. is acting as the sole book-running manager for the offering.\nGMS Ventures and Investments, an affiliate of Outlook Therapeutics' largest stockholder and strategic partner, BioLexis Pte. Ltd., has indicated an interest in purchasing directly or through an affiliate up to $20 million of the shares in the offering.\nOutlook Therapeutics will use the net proceeds for working capital and general corporate purposes, including supporting its ONS-5010 development program.\nRecently, Outlook presented pivotal safety and efficacy data from the Phase 3 NORSE TWO trial for ONS-5010 at the Retinal Subspecialty Day, AAO 2021 Annual Conference.\nONS-5010 is an investigational ophthalmic formulation of bevacizumab for use in wet age-related macular degeneration (wet AMD) and other retinal indications,\nOutlook Therapeutics plans to submit a marketing application in Q1 of 2022.","news_type":1},"isVote":1,"tweetType":1,"viewCount":154,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":4,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/874669498"}
精彩评论